# Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

> **NCT00242827** · PHASE2 · TERMINATED · sponsor: **Cephalon**

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Oral CEP-701

## Key facts

- **NCT ID:** NCT00242827
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** — (—)
- **Last updated:** 2012-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242827, "Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00242827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*